|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF273 |
Gene summary for ZNF273 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF273 | Gene ID | 10793 |
| Gene name | zinc finger protein 273 | |
| Gene Alias | HZF9 | |
| Cytomap | 7q11.21 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q14593 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10793 | ZNF273 | LZE4T | Human | Esophagus | ESCC | 1.22e-05 | 8.82e-02 | 0.0811 |
| 10793 | ZNF273 | LZE24T | Human | Esophagus | ESCC | 3.25e-10 | 2.52e-01 | 0.0596 |
| 10793 | ZNF273 | P1T-E | Human | Esophagus | ESCC | 2.83e-08 | 3.31e-01 | 0.0875 |
| 10793 | ZNF273 | P2T-E | Human | Esophagus | ESCC | 9.47e-18 | 3.23e-01 | 0.1177 |
| 10793 | ZNF273 | P4T-E | Human | Esophagus | ESCC | 8.74e-12 | 3.14e-01 | 0.1323 |
| 10793 | ZNF273 | P5T-E | Human | Esophagus | ESCC | 4.26e-14 | 2.47e-01 | 0.1327 |
| 10793 | ZNF273 | P8T-E | Human | Esophagus | ESCC | 2.23e-16 | 2.33e-01 | 0.0889 |
| 10793 | ZNF273 | P9T-E | Human | Esophagus | ESCC | 3.88e-07 | 1.37e-01 | 0.1131 |
| 10793 | ZNF273 | P10T-E | Human | Esophagus | ESCC | 4.94e-18 | 3.17e-01 | 0.116 |
| 10793 | ZNF273 | P12T-E | Human | Esophagus | ESCC | 2.21e-16 | 3.60e-01 | 0.1122 |
| 10793 | ZNF273 | P15T-E | Human | Esophagus | ESCC | 2.29e-12 | 2.57e-01 | 0.1149 |
| 10793 | ZNF273 | P16T-E | Human | Esophagus | ESCC | 5.67e-15 | 1.73e-01 | 0.1153 |
| 10793 | ZNF273 | P20T-E | Human | Esophagus | ESCC | 3.64e-09 | 2.29e-01 | 0.1124 |
| 10793 | ZNF273 | P21T-E | Human | Esophagus | ESCC | 4.65e-11 | 2.08e-01 | 0.1617 |
| 10793 | ZNF273 | P22T-E | Human | Esophagus | ESCC | 8.33e-12 | 2.33e-01 | 0.1236 |
| 10793 | ZNF273 | P23T-E | Human | Esophagus | ESCC | 1.05e-03 | 1.16e-01 | 0.108 |
| 10793 | ZNF273 | P24T-E | Human | Esophagus | ESCC | 1.08e-08 | 6.19e-02 | 0.1287 |
| 10793 | ZNF273 | P26T-E | Human | Esophagus | ESCC | 9.57e-11 | 1.40e-01 | 0.1276 |
| 10793 | ZNF273 | P27T-E | Human | Esophagus | ESCC | 1.51e-18 | 3.37e-01 | 0.1055 |
| 10793 | ZNF273 | P28T-E | Human | Esophagus | ESCC | 1.77e-17 | 3.49e-01 | 0.1149 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF273 | SNV | Missense_Mutation | novel | c.1391G>T | p.Gly464Val | p.G464V | Q14593 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF273 | SNV | Missense_Mutation | novel | c.893T>C | p.Val298Ala | p.V298A | Q14593 | protein_coding | tolerated(1) | benign(0.001) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| ZNF273 | SNV | Missense_Mutation | c.829C>G | p.Leu277Val | p.L277V | Q14593 | protein_coding | deleterious(0) | possibly_damaging(0.651) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ZNF273 | SNV | Missense_Mutation | c.1154A>T | p.Gln385Leu | p.Q385L | Q14593 | protein_coding | tolerated(0.7) | benign(0.096) | TCGA-Q1-A73S-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| ZNF273 | SNV | Missense_Mutation | rs762338510 | c.715T>C | p.Cys239Arg | p.C239R | Q14593 | protein_coding | deleterious(0.04) | benign(0.263) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| ZNF273 | SNV | Missense_Mutation | c.1284N>C | p.Lys428Asn | p.K428N | Q14593 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF273 | SNV | Missense_Mutation | novel | c.1369C>T | p.Pro457Ser | p.P457S | Q14593 | protein_coding | deleterious(0.05) | benign(0.389) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF273 | SNV | Missense_Mutation | novel | c.161T>C | p.Leu54Pro | p.L54P | Q14593 | protein_coding | deleterious(0.01) | possibly_damaging(0.833) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF273 | SNV | Missense_Mutation | rs758031517 | c.380N>A | p.Ser127Tyr | p.S127Y | Q14593 | protein_coding | deleterious(0.04) | benign(0.077) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| ZNF273 | SNV | Missense_Mutation | c.607A>G | p.Lys203Glu | p.K203E | Q14593 | protein_coding | tolerated(0.43) | benign(0.344) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |